{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:57:10Z","timestamp":1772121430514,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.modpat.2025.100733","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:24:49Z","timestamp":1738945489000},"page":"100733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in Patients Receiving Neoadjuvant Chemotherapy for Hormone Receptor-Positive HER2-Negative Breast Cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Thais Perez","family":"Vazquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-0214","authenticated-orcid":false,"given":"Rodrigo","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Pierobon","family":"Gomes da Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Wladimir","family":"Silva Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Nalesso","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund Chada","family":"Baracat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Roberto","family":"Filassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.modpat.2025.100733_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12885-019-5442-6","article-title":"Prognostic models for breast cancer: a systematic review","volume":"19","author":"Phung","year":"2019","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.modpat.2025.100733_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.modpat.2025.100733_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.20.00853","article-title":"Molecular Drivers of Oncotype DX, prosigna, endopredict, and the breast cancer index: a transATAC Study","volume":"39","author":"Buus","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100733_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.modpat.2025.100733_bib5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/modpathol.2008.54","article-title":"Histopathologic variables predict Oncotype DX recurrence score","volume":"21","author":"Flanagan","year":"2008","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2025.100733_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/modpathol.2013.36","article-title":"Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis","volume":"26","author":"Klein","year":"2013","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100733_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/modpathol.2015.50","article-title":"Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score","volume":"28","author":"Turner","year":"2015","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100733_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-016-4093-4","article-title":"Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset","volume":"162","author":"Harowicz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.modpat.2025.100733_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.humpath.2020.11.006","article-title":"Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX\u00ae recurrence score using Magee Equations and Magee Decision Algorithm\u2122","volume":"108","author":"Remou\u00e9","year":"2021","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2025.100733_bib10","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41379-020-0521-4","article-title":"The healthcare value of the Magee Decision Algorithm\u2122: use of Magee Equations\u2122 and mitosis score to safely forgo molecular testing in breast cancer","volume":"33","author":"Bhargava","year":"2020","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2025.100733_bib11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/modpathol.2017.41","article-title":"Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative\/equivocal breast tumors","volume":"30","author":"Farrugia","year":"2017","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100733_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5152\/ejbh.2020.5338","article-title":"The correlation of Magee EquationsTM and Oncotype DX\u00ae Recurrence Score from core needle biopsy tissues in predicting response to neoadjuvant chemotherapy in ER+ and HER2- breast cancer","volume":"16","author":"Soran","year":"2020","journal-title":"Eur J Breast Health"},{"issue":"1","key":"10.1016\/j.modpat.2025.100733_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41379-020-0620-2","article-title":"Magee Equations\u2122 and response to neoadjuvant chemotherapy in ER+\/HER2-negative breast cancer: a multi-institutional study","volume":"34","author":"Bhargava","year":"2021","journal-title":"Mod Pathol"},{"issue":"28","key":"10.1016\/j.modpat.2025.100733_bib14","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2025.100733_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3747\/co.v15i6.242","article-title":"Residual cancer burden in locally advanced breast cancer: a superior tool","volume":"15","author":"Nahleh","year":"2008","journal-title":"Curr Oncol"},{"issue":"13","key":"10.1016\/j.modpat.2025.100733_bib16","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1245\/s10434-019-07741-w","article-title":"Validation of residual cancer burden as prognostic factor for breast cancer patients after neoadjuvant therapy","volume":"26","author":"M\u00fcller","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100733_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jclinpath-2021-207771","article-title":"Validation of the Residual Cancer Burden Index as a prognostic tool in women with locally advanced breast cancer treated with neoadjuvant chemotherapy","volume":"76","author":"Gomes da Cunha","year":"2023","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2025.100733_bib18","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100733_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5858\/arpa.2013-0231-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum","volume":"138","author":"Bartley","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.modpat.2025.100733_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000531117","article-title":"Conventional tools for predicting satisfactory response to neoadjuvant chemotherapy in HR+\/HER2- breast cancer patients","volume":"18","author":"Oprea","year":"2023","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"10.1016\/j.modpat.2025.100733_bib21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.modpat.2025.100733_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/GO.20.00440","article-title":"Epidemiological analyses reveal a high incidence of breast cancer in young women in Brazil","volume":"7","author":"Orlandini","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.modpat.2025.100733_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.breast.2019.01.008","article-title":"Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study","volume":"44","author":"Simon","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.modpat.2025.100733_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102437","article-title":"Characteristics and prognosis of young breast cancer patients treated in a public comprehensive cancer centre in Brazil: a retrospective cohort study","volume":"86","author":"Carreiro","year":"2023","journal-title":"Cancer Epidemiol"},{"issue":"13","key":"10.1016\/j.modpat.2025.100733_bib25","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.3390\/ijerph17134884","article-title":"Does breast cancer increasingly affect younger women?","volume":"17","author":"Konat-B\u0105ska","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"10.1016\/j.modpat.2025.100733_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10552-016-0726-5","article-title":"Breast cancer survival among young women: a review of the role of modifiable lifestyle factors","volume":"27","author":"Brenner","year":"2016","journal-title":"Cancer Causes Control"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T11:35:51Z","timestamp":1750246551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0893395225000298"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100733","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in Patients Receiving Neoadjuvant Chemotherapy for Hormone Receptor-Positive HER2-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100733"}}